Nektar治疗技术公司将向Ampersand出售其阿拉巴马州设施和PEGEG联系业务90M美元。 Nektar Therapeutics will sell its Alabama facility and PEGylation business to Ampersand for $90M.
Nektar治疗公司计划向Ampersand Capital Partners出售其阿拉巴马制造设施和PEGelation试剂供应业务,价值9 000万美元,包括7 000万美元现金和2 000万美元股本。 Nektar Therapeutics plans to sell its Alabama manufacturing facility and PEGylation reagent supply business to Ampersand Capital Partners for $90 million, comprising $70 million in cash and $20 million in equity. 预计这项交易将在12月2日之前完成,允许Nektar为Ampersand的董事会指定一名代表。 The deal is expected to finalize by December 2, allowing Nektar to appoint a representative to Ampersand's board. 预计这笔交易将加强Nektar的财务稳定,将其现金跑道延长到2026年底。 This transaction is projected to enhance Nektar's financial stability, extending its cash runway into late 2026.